We are pleased to announce the appointment of Jacob Licht as Chief Executive Officer of Exo-Top Inc. (“Exo-Top”), a wholly owned subsidiary of the Company, and as Vice President, Corporate Development at NurExone. Exo-Top is a U.S.-based GMP-compliant exosome manufacturing site and will be the pillar of the Company’s global supply chain and commercialization strategy.
Mr. Licht’s new roles will include leading the establishment of Exo-Top’s manufacturing capabilities, developing strategic partnerships, and developing corporate initiatives aligned with NurExone’s path toward clinical readiness and future fundraising.